6-氮杂尿苷-2,3,5-三乙酸酯 | 2169-64-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 6-氮杂尿苷-2,3,5-三乙酸酯
• 中文别名: 氮尿苷乙酯；阿扎立平；阿托立平
• 英文名称: 2',3',5'-tri-O-acetyl-6-azauridine
• 英文别名: 2-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1,2,4-triazine-3,5-dione；1-(2,3,5-Tri-O-acetyl-β-D-ribofuranosyl)-6-azauracil；6-azauridine-2',3',5'-tri-O-acetate；6-azauridine-2',3',5'-triacetate；2',3',5'-triacetyl-6-azauridine；6-azauridine triacetate；Azaribine；[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(3,5-dioxo-1,2,4-triazin-2-yl)oxolan-2-yl]methyl acetate
• CAS: 2169-64-4
• 化学式: C₁₄H₁₇N₃O₉
• 分子量: 371.304
• InChiKey: QQOBRRFOVWGIMD-OJAKKHQRSA-N

物化性质

• 熔点：
  99-101 °C(lit.)
• 沸点：
  501.01°C (rough estimate)
• 密度：
  1.3535 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  150
• 氢给体数：
  1
• 氢受体数：
  10

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  2
• RTECS号：
  XY8577000

反应信息

• 作为反应物：
  描述：

  6-氮杂尿苷-2,3,5-三乙酸酯 在 氨 、 氯化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 三氯氧磷 作用下， 以 吡啶 、 甲醇 、 乙腈 为溶剂， 反应 52.5h， 生成 6-氮杂胞苷
  参考文献：
  名称：

  Biochemical Detection of Cytidine Protonation within RNA

  摘要：

  Perturbation of active site functional group pK(a)s is an important strategy employed by protein enzymes to achieve catalysis. There is increasing evidence to indicate that RNAs also utilize functional group pK(a) perturbation for folding and reactivity. one of the best candidates for a functionally relevant pK(a) perturbation is the N3 of C (pK(a) 4.2), which could be sufficiently raised to allow protonation near physiological pH. Here we report the synthesis and use of a series of alpha -phosphorothioate tagged cytidine analogues whose altered N3 pK(a)s make it possible to efficiently detect functionally relevant protonation events by nucleotide analogue interference mapping. 6-Azacytidine (n(6)C alphaS) and 5-fluorocytidine (f(5)C alphaS) both have enhanced acidity at the N3 position (pK(a) 2.6 and 2.3, respectively) but leave the hydrogen bonding face of C otherwise unaffected. In contrast, pseudoisocytidine (Psi iC alphaS) is a charge neutral analogue that mimics the hydrogen bonding character of protonated C. To test the utility of these analogues, we characterized the C300(+)-G97-C277 mutant form of the Tetrahymena group I intron, which is predicted to require C300 protonation for ribozyme folding and reactivity. At neutral to alkaline pHs, C300 was the only site of n(6)C alphaS and f(5)C alphaS interference within the intron, yet both interferences were rescued at acidic pH. Furthermore,Psi iC alphaS substitution at C300 resulted in enhanced activity at alkaline pHs, consistent with the presence of an N3 proton under the pH conditions studied. Interference mapping with these analogues provides an efficient and sensitive means to identify every site within an RNA where cytidine protonation is important for RNA function and may make it possible to identify C's that participate in general acid/base catalysis within ribozyme active sites.

  DOI：

  10.1021/ja001918t
• 作为产物：
  描述：

  D-ribose 在 吡啶 作用下， 生成 6-氮杂尿苷-2,3,5-三乙酸酯
  参考文献：
  名称：

  一种新的简单核苷合成

  摘要：

  将过量的D-核糖或D-葡萄糖与6-氮杂嘧啶或N-苯甲酰腺嘌呤进行全硅烷基化，然后与三氟甲磺酸三甲基甲硅烷基酯在乙腈中于80°缩合，得到相应的全硅烷基化的核苷。用甲醇进行硅烷基化并在SiO 2上进行色谱分离，可得到纯净的游离核苷，收率高达70％。

  DOI：

  10.1016/0040-4039(95)01667-7

文献信息

• Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
  申请人：YOSHIDA Kenji

  公开号：US20100111852A1

  公开（公告）日：2010-05-06

  Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.

  提供了特异性结合于细胞表面表达的Claudin 3的单克隆抗体。本发明的抗体对于具有增强Claudin 3表达的癌症的诊断是有用的，如卵巢癌、前列腺癌、乳腺癌、子宫癌、肝癌、肺癌、胰腺癌、胃癌、膀胱癌和结肠癌。本发明提供了对这些癌症细胞具有细胞毒作用的单克隆抗体。公开了诱导Claudin 3表达细胞受损的方法以及通过与Claudin 3结合抗体接触Claudin 3表达细胞来抑制Claudin 3表达细胞增殖的方法。本申请还公开了癌症的诊断或治疗方法。
• [EN] COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035360A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  化合物、使用方法和制备抑制补体因子D的方法，包括式（I）的药用盐或其组合物。本文描述的抑制剂针对因子D并抑制或调节补体级联反应。本文描述的因子D的抑制剂减少了过度激活的补体。
• [EN] ALKYNE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS ALCYNE POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035415A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供含有公式I、I"和I'"的补体因子D抑制剂、使用方法和制备过程，或其药物可接受的盐或组合物。本文所述的抑制剂针对因子D并抑制或调节补体级联反应。本文所述的因子D抑制剂减少了补体的过度激活。
• [EN] ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS ARYLE, HÉTÉROARYLE, ET HÉTÉROCYCLIQUES POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035409A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

  提供含有公式I、I"和I'"的补体因子D抑制剂、使用方法和制备过程，或其药物可接受的盐或组合物。本文所述的抑制剂针对因子D并抑制或调节补体级联反应。本文所述的因子D抑制剂减少了补体的过度激活。
• [EN] MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS MACROCYCLIQUES DESTINÉS AU TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2018160892A1

  公开（公告）日：2018-09-07

  Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

  提供大环补体因子D抑制剂、药物组合物及其用途，以及它们的制造工艺。所提供的化合物包括公式I、公式II、公式III、公式IV、公式V、公式VI、公式VII和公式VIII或其药用可接受的盐、前药、同位素类似物、N-氧化物或孤立的同分异构体，可选地存在于药用可接受的组合物中。此处描述的抑制剂针对因子D并抑制或调节补体级联反应。

表征谱图